0000000000200909

AUTHOR

Tjendimin Tjandrawan

showing 2 related works from this author

A novel epitope of N-CAM defines precursors of human adherent NK cells

2004

AbstractActivated, adherent natural killer (A-NK) cells represent a distinct subpopulation of interleukin (IL)-2-stimulated NK cells, which are selectively endowed with the increased expression of integrins and ability to adhere to solid surfaces, migrate into, infiltrate, and destroy cancerous tissues. The present study defines the phenotype and functions of precursors of A-NK (pre-A-NK) cells in humans. Peripheral blood pre-A-NK cells, in contrast to the rest of NK cells, express a novel epitope of CD56 neuronal cell adhesion molecule, termed ANK-1, and increased cell-surface levels of integrins. Pre-A-NK cells also express low levels of CD56 and CD161, and some express CD162 receptor, do…

Cytotoxicity ImmunologicIntegrinsLymphoid TissueImmunologyCell CountBiologyCD49bImmunophenotypingEpitopesInterleukin 21NK-92Cell AdhesionHumansImmunology and AllergyCell LineageLectins C-TypeAntigen-presenting cellCells CulturedCell ProliferationMembrane GlycoproteinsLymphokine-activated killer cellStem CellsJanus kinase 3Cell MembraneReceptors IgGAntibodies MonoclonalCell DifferentiationCell BiologyNatural killer T cellCD56 AntigenCell biologyKiller Cells NaturalChemotaxis LeukocyteAntigens SurfaceInterleukin 12Interleukin-2NK Cell Lectin-Like Receptor Subfamily BJournal of Leukocyte Biology
researchProduct

Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Autologous Human Dendriphages Pul…

1998

The recent identification of tumor-associated antigens and tumor-associated antigen-derived peptide epitopes recognized by cytolytic T lymphocytes (CTLs) in the context of major histocompatibility complex (MHC) class I molecules has prompted the development of peptide-based vaccines for the treatment of human cancers, particularly melanoma. The design of such clinical protocols requires an understanding of the inherent immunogenicity of the peptide(s) and a choice of a facilitating adjuvant promoting cellular immunity against these peptides. We have evaluated the abilities of a series of defined synthetic peptide epitopes derived from MART- I/Melan-A, gp100, tyrosinase. and MAGE-3 or unfrac…

PharmacologyCancer ResearchCellular immunityImmunogenicityImmunologychemical and pharmacologic phenomenaDendritic cellBiologyMajor histocompatibility complexEpitopeCTL*Immune systemAntigenImmunologybiology.proteinImmunology and AllergyneoplasmsJournal of Immunotherapy
researchProduct